KalVista Pharmaceuticals Unveils Promising Data on Sebetralstat for On-Demand HAE Attack Treatment at EAACI Congress 2025

Reuters

2025/06/16

KalVista Pharmaceuticals Unveils Promising Data on Sebetralstat for On-Demand HAE Attack Treatment at EAACI Congress 2025

KalVista Pharmaceuticals Inc. recently announced the presentation of new data at the European Academy of Allergy and Clinical Immunology Congress 2025 in Glasgow, United Kingdom. The data focus on the efficacy of sebetralstat for the on-demand treatment of hereditary angioedema $(HAE)$ attacks among patients receiving long-term prophylaxis. The KONFIDENT-S study highlighted the challenges of adherence to long-term prophylaxis and the need for effective on-demand treatments. Results showed that oral sebetralstat provided rapid relief for breakthrough attacks, with a median time to symptom relief of 1.3 hours. These findings were presented at the congress, indicating the potential of sebetralstat as a complementary treatment to existing long-term prophylaxis options. Links to the presentations are available on the KalVista website under Publications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250616564483) on June 16, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2543679715"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543679715\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543679715?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-16 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543679715","market":"nz","top_or_hot":-1,"title":"KalVista Pharmaceuticals Unveils Promising Data on Sebetralstat for On-Demand HAE Attack Treatment at EAACI Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      KalVista Pharmaceuticals Unveils Promising Data on Sebetralstat for On-Demand HAE Attack Treatment at EAACI Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        KalVista Pharmaceuticals Inc. recently announced the presentation of new data at the European Academy of Allergy and Clinical Immunology Congress 2025 in Glasgow, United Kingdom. The data focus on the efficacy of sebetralstat for the on-demand treatment of hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> attacks among patients receiving long-term prophylaxis. The KONFIDENT-S study highlighted the challenges of adherence to long-term prophylaxis and the need for effective on-demand treatments. Results showed that oral sebetralstat provided rapid relief for breakthrough attacks, with a median time to symptom relief of 1.3 hours. These findings were presented at the congress, indicating the potential of sebetralstat as a complementary treatment to existing long-term prophylaxis options. Links to the presentations are available on the KalVista website under Publications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KALV\">Kalvista Pharmaceuticals Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250616564483) on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KalVista Pharmaceuticals Unveils Promising Data on Sebetralstat for On-Demand HAE Attack Treatment at EAACI Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKalVista Pharmaceuticals Unveils Promising Data on Sebetralstat for On-Demand HAE Attack Treatment at EAACI Congress 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-16 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      KalVista Pharmaceuticals Unveils Promising Data on Sebetralstat for On-Demand HAE Attack Treatment at EAACI Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        KalVista Pharmaceuticals Inc. recently announced the presentation of new data at the European Academy of Allergy and Clinical Immunology Congress 2025 in Glasgow, United Kingdom. The data focus on the efficacy of sebetralstat for the on-demand treatment of hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> attacks among patients receiving long-term prophylaxis. The KONFIDENT-S study highlighted the challenges of adherence to long-term prophylaxis and the need for effective on-demand treatments. Results showed that oral sebetralstat provided rapid relief for breakthrough attacks, with a median time to symptom relief of 1.3 hours. These findings were presented at the congress, indicating the potential of sebetralstat as a complementary treatment to existing long-term prophylaxis options. Links to the presentations are available on the KalVista website under Publications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KALV\">Kalvista Pharmaceuticals Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250616564483) on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KALV","symbol_name":"Kalvista Pharmaceuticals Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL3cdJky:1","article_id":"2543679715","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543679715","pubTimestamp":1750071638,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"KalVista Pharmaceuticals Inc. recently announced the presentation of new data at the European Academy of Allergy and Clinical Immunology Congress 2025 in Glasgow, United Kingdom. The data focus on the efficacy of sebetralstat for the on-demand treatment of hereditary angioedema  attacks among patients receiving long-term prophylaxis. The KONFIDENT-S study highlighted the challenges of adherence to long-term prophylaxis and the need for effective on-demand treatments. Results showed that oral sebetralstat provided rapid relief for breakthrough attacks, with a median time to symptom relief of 1.3 hours. These findings were presented at the congress, indicating the potential of sebetralstat as a complementary treatment to existing long-term prophylaxis options. Links to the presentations are available on the KalVista website under Publications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KALV":"Kalvista Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"KalVista Pharmaceuticals在2025年EAACI大会上公布了Sebetralstat用于按需HAE发作治疗的有希望的数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALV":0.9},"content_text":"KalVista Pharmaceuticals Unveils Promising Data on Sebetralstat for On-Demand HAE Attack Treatment at EAACI Congress 2025\n    \n\n        KalVista Pharmaceuticals Inc. recently announced the presentation of new data at the European Academy of Allergy and Clinical Immunology Congress 2025 in Glasgow, United Kingdom. The data focus on the efficacy of sebetralstat for the on-demand treatment of hereditary angioedema $(HAE)$ attacks among patients receiving long-term prophylaxis. The KONFIDENT-S study highlighted the challenges of adherence to long-term prophylaxis and the need for effective on-demand treatments. Results showed that oral sebetralstat provided rapid relief for breakthrough attacks, with a median time to symptom relief of 1.3 hours. These findings were presented at the congress, indicating the potential of sebetralstat as a complementary treatment to existing long-term prophylaxis options. Links to the presentations are available on the KalVista website under Publications.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250616564483) on June 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}